drugset / Trial / NCT00056173
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
Phase 1/2
Completed
43 enrolled
Aptose Biosciences Inc.
University of Chicago · collabWake Forest University · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
Timeline
- Start
- 2002-03
- Primary completion
- 2004-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GTI-2040 | Antisense oligonucleotide | — | — |